ClinicalTrials.gg
CompletedNCT03992339SEARCHUpdated Feb 7, 2025Results posted

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 2 interventional study of ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Antengene Corporation. Completed at 18 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Antengene Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse — 1 open to participants now, 4 under way, 1 of them phase 3. selinexor · Lymphoma, Large B-Cell, Diffuse.

Enrollment
5th of 11
60 · median 54
Started
2020
with 1 other
Phase 2
3 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
3 of 11
Antengene Corporation

Among the 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 2, and was the 6th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse is open now. Recruiting first, the newest first:

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing selinexor in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Read the detailed description

This is an open-label, single arm, and registered study. About 60 patients with relapsed/refractory DLBCL plan to be enrolled in about 10 study sites of the study. It is planned that at least 50% (\~30 patients) will have the GCB subtype of DLBCL. Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle. Patients should remain on the study treatment of ATG-010, until either PD or occurrence of unacceptable toxicity.

03

Conditions studied

  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient must provide form (ICF) prior to the first screening procedure.
  2. Age ≥18 years.
  3. performance status of ≤ 2.
  4. Patients should have estimated of >3 months at study entry.
  5. Previously treated, confirmed de novo DLBCL, or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma).
  6. Patients must have received at least 2 but no more than 5 previous systemic regimens for the treatment of their de novo or transformed DLBCL.
  7. Documented clinical or radiographic evidence of progressive DLBCL prior to dosing.
  8. Patients must have per the revised criteria for response assessment of lymphoma (Cheson, 2014).
  9. Patients must not be eligible for high-dose chemotherapy with stem cell transplantation rescue.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are pregnant or lactating.
  2. DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkin's lymphoma +NHL), or DLBCL transformed from diseases other than indolent NHL or Richter's.
  3. Primary mediastinal (thymic) large B-cell lymphoma.
  4. Known central nervous system lymphoma or meningeal involvement.
  5. Patients whose most recent systemic anticancer therapy include radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy other than \< 6 weeks prior to first dose of study drug.
  6. Patients who have not recovered to Grade ≤ 1 adverse events, or to their baseline, from their most recent systemic anti-DLBCL therapy.
  7. Patients with active after stem cell transplantation. At least 4 months must have elapsed since completion of allogeneic stem cell transplantation.
  8. Major surgery within 2 weeks of first dose of study treatment of ATG-010.
  9. Any life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
  10. Active virus or virus infection.
  11. Known infection.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ATG-010

    Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010.

    Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    ORR is defined as the proportion of patients who achieve either complete response (CR) or partial response (PR) according to the revised criteria for response assessment of lymphoma (2014 Lugano criteria: A complete metabolic response requires Score 1, 2, or 3 with or without a residual mass on 5PS(5-point scale using PET-CT). A PR requires a decrease by more than 50% in the sum of the product of the perpendicular diameters of up to six representative nodes or extranodal lesions.)

    Time frame: 12 months

Secondary outcomes

  1. PFS

    PFS is defined as the duration from start of selinexor treatment to time of central imaging laboratory determined PD (based on 2014 Lugano criteria: Progressive metabolic disease requires Score 4 or 5 with an increase in intensity of uptake from baseline. Progressive disease by CT criteria only requires an increase in the PPDs of a single node by ≥ 50%.)or death from any cause, whichever occurs first.

    Time frame: 12 months

07

Results

Posted Feb 7, 2025

Participant flow

Participant flow — Overall Study
MilestoneATG-010
Started60
Completed60
Not completed0

Outcome measures

PrimaryORR

ORR is defined as the proportion of patients who achieve either complete response (CR) or partial response (PR) according to the revised criteria for response assessment of lymphoma (2014 Lugano criteria: A complete metabolic response requires Score 1, 2, or 3 with or without a residual mass on 5PS(5-point scale using PET-CT). A PR requires a decrease by more than 50% in the sum of the product of the perpendicular diameters of up to six representative nodes or extranodal lesions.)

Time frame:
12 months
Reported as:
Count of participants · Participants
ORR
ParticipantsATG-010
ORR13
SecondaryPFS

PFS is defined as the duration from start of selinexor treatment to time of central imaging laboratory determined PD (based on 2014 Lugano criteria: Progressive metabolic disease requires Score 4 or 5 with an increase in intensity of uptake from baseline. Progressive disease by CT criteria only requires an increase in the PPDs of a single node by ≥ 50%.)or death from any cause, whichever occurs first.

Time frame:
12 months
Reported as:
Median · month
PFS
monthATG-010
PFS1.87 (1.81 to 2.10)

Adverse events

Collected over From study drug dosed to 30 days after last study drug dose, up to 44 months, SAE was collected from consent, an average of 3.7 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATG-01043/60 (71.7%)24/60 (40%)60/60 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventATG-010
Platelet count dicreasedInvestigations9/60
Neutrophil count decreasedInvestigations3/60
White blood cell count decreasedInvestigations2/60
PyrexiaGeneral disorders2/60
DysphagiaGastrointestinal disorders1/60
NauseaGastrointestinal disorders1/60
GastritisGastrointestinal disorders1/60
AscitesGastrointestinal disorders1/60
DiarrhoeaGastrointestinal disorders1/60
Abdominal painGastrointestinal disorders1/60
Most frequent other events
Showing 10 of 24
Most frequent other events
EventATG-010
Platelet count decreasedInvestigations59/60
White blood cell count decreasedInvestigations49/60
Neutrophil count decreasedInvestigations48/60
AnemiaBlood and lymphatic system disorders45/60
Appetite decreasedGastrointestinal disorders37/60
NauseaGastrointestinal disorders35/60
Weight decreasedInvestigations23/60
VomitingGastrointestinal disorders20/60
DiarrhoeaGastrointestinal disorders19/60
Lymphocyte count decreasedInvestigations18/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)ATG-010
Mean58.8 ± 11.36
Sex: Female, Male
Sex: Female, Male(Participants)ATG-010
Female27
Male33
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ATG-010
Asian60
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)ATG-010
Mean23.94 ± 3.089
08

Study locations

18 sites
  • Anhui Province Cancer Hospital
    Hefei, Anhui 230000, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Chongqing Universtity Cancer Hospital
    Chongqing, Chongqing 400000, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430000, China
  • Wuhan Union Hospital
    Wuhan, Hubei 430022, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • The First Affilate Hospital with Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • The First Bethune Hospital of Jilin University
    Chang chun, Jilin 130021, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116027, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin blood research institute
    Tianjin, Tianjin 300052, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin 300060, China
  • Cancer Hospital of the University of the Chinese Academy of Sciences
    Hangzhou, Zhejiang 310022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in May 2023, 37 months.

Results were first posted in Feb 2025, 1 year 8 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 37 months is close to that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2019
First posted
Jun 20, 2019
StartActual
Apr 9, 2020
Primary completionActual
May 31, 2023
CompletionActual
Dec 1, 2023
Results first posted
Feb 7, 2025
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03992339
Lead sponsor
Antengene Corporation
Responsible party
Sponsor
First posted
Jun 20, 2019
Start date
Apr 9, 2020
Primary completion
May 31, 2023
Completion
Dec 1, 2023
Results posted
Feb 7, 2025
Last update
Feb 7, 2025

Study contacts

Bingshan Liu, MD
study director · Medical Monitor

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion